AGEN1181 is a multipurpose, second-generation “Fc-engineered” anti-CTLA-4 antibody with enhanced tumor fighting abilities, designed to generate responses in a larger number of patients and improve immunogenicity.
AGEN1181, has achieved complete and partial responses, alone and in combination with AGEN’s anti-PD-1 (balstilimab / AGEN2034) in early clinical trials (as of April 2020).
Discovery of AGEN1181 and its Mechanism of Action
Agenus scientists discovered a new mechanism of action in which a specialized domain of the antibody engages with receptors on other immune cells to significantly bolster antitumor immunity. This discovery was published in Cancer Cell.
To develop AGEN1181, Agenus leveraged the above discovery to modify a part of the antibody known as the Fc region, which interacts with other immune cells to enhance antitumor immunity. In pre-clinical studies, this “Fc-engineered” antibody significantly improved the cross-talk between antigen presenting cells (APCs) and T cells. In cancer immunotherapy, such an interaction is necessary to mount a potent immune response against cancer.
Latest Clinical Trials
Phase 1, multicenter study to evaluate the safety, tolerability, PK, and PD profiles of a novel Fc-engineered IgG1 anti-CTLA-4 human monoclonal antibody (AGEN1181) monotherapy and in combination with a human monoclonal IgG4 antibody (AGEN2034)
Latest Publications and Abstracts
June 22-24, 2020
Expanding the Therapeutic Potential of anti-PD-1 and anti-CTLA-4 Therapy with Innovative Fc Engineering and Rationale Combinations for the Treatment of Solid Tumors. Tanne, et al.
May 29-31, 2020
AGEN1181, a Clinical Stage Fc-Engineered anti-CTLA-4 Antibody with Improved Therapeutic Potential for the Treatment of Patients with Advanced Malignancies. O'Day, et al.
November 18, 2019
New mechanistic insights from TME reconditioning by an Fc engineered anti-CTLA-4 antibody. Vincent, et al.